Kymera Therapeutics (KYMR) AI Stock Analysis

• Market Cap: $3.08B
• Dividend Yield: N/A
• Average Volume (3M): 976.37K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.61
• Revenue Growth: -25.85%
• EPS Growth: -23.89%
• Country: US
• Employees: 208
• Sector: Healthcare
• Sector Strength: 58
• Industry: Biotechnology
• EPS (TTM): -0.82
• Shares Outstanding: 65,119,570
• 10 Day Avg. Volume: 1,692,913
• 30 Day Avg. Volume: 976,366
• PEG Ratio: -0.38
• Price to Book (P/B): -19.91
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 85.25
• Enterprise Value/Market Cap: 0.46
• Enterprise Value/Revenue: 5.06
• Enterprise Value/Gross Profit: 24.22
• Enterprise Value/Ebitda: -1.87
• 1Y Price Target: $60.50
• Price Target Upside: 27.93% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 15

• Rating: 61 Neutral
• Price Target: $50.00 ▲(5.73%Upside)

Kymera Therapeutics' overall stock score reflects a mix of strong technical indicators and promising corporate developments, tempered by financial challenges. The company's robust pipeline and strategic focus on high-value programs enhance its future potential, despite current profitability issues.

Positive Factors

Clinical Efficacy

The data exceeded expectations and increases confidence in its potential to show clinical efficacy as they move into AD and asthma.

Pipeline Value

The increase in pipeline value to $2.5bn is based on results providing initial validation for KT-621’s potential in multiple autoimmune indications.

Target Degradation

KT-621 achieved 90%+ STAT6 target degradation in blood and skin, with Th2 biomarker findings broadly in-line with dupilumab HV data.

Negative Factors

Clinical Trials

The company plans to initiate phase 2b dose ranging trials in AD and asthma, where they will likely evaluate 3 doses to select the phase 3 dose for each indication.

Phase 1b Trial

The first-in-human trial data from KT-621, a STAT6 degrader, considerably de-risks the program for the upcoming Phase 1b trial and potentially the two Phase 2s.

Kymera Therapeutics Business Overview & Revenue Model

Company Description

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

How the Company Makes Money

Kymera Therapeutics makes money primarily through the development and potential commercialization of its drug candidates, leveraging its proprietary targeted protein degradation platform. Key revenue streams include research and development collaborations, milestone payments, and potential royalties from partnerships with larger pharmaceutical companies. These partnerships, such as those with Sanofi and Vertex Pharmaceuticals, provide funding and resources needed to advance Kymera's drug candidates through clinical trials. Additionally, as drug candidates progress and potentially receive regulatory approval, the company stands to earn revenue from product sales and licensing agreements.

Kymera Therapeutics Financial Statement Overview

Summary

Kymera Therapeutics exhibits financial challenges typical of many biotechnology firms, characterized by heavy R&D investments leading to negative earnings and cash flow. While the balance sheet reflects a strong equity position, indicating potential for future financing, current operations remain under pressure from ongoing losses and negative cash flows. Investors should be cautious and consider the trajectory of product development and potential for revenue growth in the near future.

Income Statement

Kymera Therapeutics shows a declining revenue growth with a drop from the previous periods, and consistent negative net profit margins indicating an ongoing unprofitable state. The gross profit margin is solid as all revenue translates directly to gross profit due to likely no cost of goods sold, but the EBIT and EBITDA margins are significantly negative, reflecting high operational expenses that overshadow revenues.

Balance Sheet

The company maintains a robust equity position with a strong equity ratio, but the debt-to-equity ratio suggests manageable leverage. However, the return on equity remains negative due to persistent losses, which raises concerns about profitability. The balance sheet shows a solid cash position, but the high liabilities relative to equity warrant caution.

Cash Flow

Kymera Therapeutics faces negative free cash flow, which has deteriorated further, indicating pressure on cash generation. The operating cash flow is significantly negative, raising concerns about the company's ability to fund operations without external financing. The free cash flow to net income ratio is unreliable due to negative values, highlighting cash management challenges.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
58.88M	47.07M	78.59M	46.83M	72.83M	34.03M
	Gross Profit
58.88M	47.07M	78.59M	43.85M	70.44M	-28.07M
	EBIT
-278.23M	-261.63M	-165.53M	-161.26M	-100.53M	-46.30M
	EBITDA
-232.67M	-216.24M	-143.20M	-151.66M	-97.64M	-43.72M
	Net Income Common Stockholders
-240.88M	-223.86M	-146.96M	-151.83M	-98.00M	-43.95M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
463.15M	488.74M	374.88M	559.49M	567.61M	458.73M
	Total Assets
918.31M	978.03M	575.76M	603.13M	605.90M	487.18M
	Total Debt
86.33M	87.76M	84.67M	17.34M	17.96M	17.99M
	Net Debt
-3.64M	-32.49M	-25.29M	-51.06M	-30.01M	-13.01M
	Total Liabilities
132.08M	142.42M	180.79M	112.98M	146.27M	203.29M
	Stockholders Equity
786.23M	835.62M	394.97M	490.15M	459.64M	283.89M
Cash Flow		Free Cash Flow
-239.96M	-207.34M	-137.31M	-155.92M	-130.54M	79.03M
	Operating Cash Flow
-234.06M	-194.50M	-102.83M	-153.09M	-128.95M	88.13M
	Investing Cash Flow
-24.86M	-404.08M	139.89M	20.52M	-99.83M	-422.59M
	Financing Cash Flow
255.35M	608.85M	4.19M	153.00M	250.28M	289.26M

Kymera Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 47.29
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KYMR, the sentiment is Positive. The current price of 47.29 is above the 20-day moving average (MA) of 38.16, above the 50-day MA of 32.49, and above the 200-day MA of 39.51, indicating a bullish trend. The MACD of 4.77 indicates Negative momentum. The RSI at 72.45 is Negative, neither overbought nor oversold. The STOCH value of 74.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KYMR.

Kymera Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HRMY	78 Outperform	$2.02B	12.71	24.71%	―	20.62%	14.08%
BCRX	66 Neutral	$2.22B	―	18.68%	―	41.67%	75.79%
KYMR	61 Neutral	$3.08B	―	-32.17%	―	-25.85%	-23.89%
AGIO	61 Neutral	$1.99B	3.06	60.26%	―	25.96%	―
Sector *	54 Neutral	$5.41B	3.27	-45.10%	3.29%	16.81%	0.02%
BEAM	45 Neutral	$1.80B	―	-38.04%	―	-82.38%	-164.76%
IRON	43 Neutral	$1.76B	―	-23.34%	―	―	-14.19%

Kymera Therapeutics Corporate Events

Kymera Therapeutics Discusses Phase 1 Study Results

On June 2, 2025, Kymera Therapeutics held a conference call to discuss the results of their Phase 1 study of KT-621, an oral STAT6 degrader for immuno-inflammatory diseases. The study’s findings are part of Kymera’s strategy to disrupt conventional treatment paradigms in immunology, potentially impacting the company’s market positioning and offering new opportunities for stakeholders.

The most recent analyst rating on (KYMR) stock is a Buy with a $46.00 price target. To see the full list of analyst forecasts on Kymera Therapeutics stock, see the KYMR Stock Forecast page.

Kymera Therapeutics Announces Positive Phase 1 Study Results

On June 2, 2025, Kymera Therapeutics announced positive results from their Phase 1 healthy volunteer study of KT-621, an oral STAT6 degrader aimed at treating immuno-inflammatory diseases. The study demonstrated robust STAT6 degradation in blood and skin, with a favorable safety profile comparable to placebo, and showed potential for KT-621 to be a transformative treatment for Th2 diseases. The company plans to advance KT-621 into Phase 1b and Phase 2b trials for atopic dermatitis and asthma, respectively, in late 2025 and early 2026.

The most recent analyst rating on (KYMR) stock is a Buy with a $46.00 price target. To see the full list of analyst forecasts on Kymera Therapeutics stock, see the KYMR Stock Forecast page.

Kymera Therapeutics Introduces KT-579 Targeting IRF5

On May 9, 2025, Kymera Therapeutics announced the introduction of KT-579, an oral degrader targeting IRF5, with potential applications in rheumatic and autoimmune diseases, expected to enter Phase 1 trials in early 2026. The company also reported progress in its KT-621 and KT-474 programs, including a $20 million milestone payment from Sanofi for the IRAK4 collaboration, and a strategic decision to focus resources on the STAT6 and IRF5 programs, extending its financial runway into 2028.